Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
  • Regulatory

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

BioPharma Dive

The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

RegulatoryInfectious DiseaseRead full story

pharminent March 23, 2026 (Last updated: March 24, 2026)

BioPharma Dive

The partners said the shot produced clinically meaningful efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

Regulatory Infectious Disease Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Apogee strengthens case for longer-lasting eczema drug
Next: How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Related Stories

  • Regulatory

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

pharminent June 2, 2026
  • Regulatory

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

pharminent June 1, 2026
  • Regulatory

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

pharminent May 29, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.